Markers of subtypes in inflammatory breast cancer studied by immunohistochemistry: Prominent expression of P-cadherin by Ben Hamida, Azza et al.
BioMed  Central
Page 1 of 8
(page number not for citation purposes)
BMC Cancer
Open Access Research article
Markers of subtypes in inflammatory breast cancer studied by 
immunohistochemistry: Prominent expression of P-cadherin
Azza Ben Hamida1,3, Intidhar S Labidi2, Karima Mrad4, Emmanuelle Charafe-
Jauffret1,5,6, Saïda Ben Arab3, Benjamin Esterni7, Luc Xerri5, Patrice Viens6,8, 
François Bertucci1,6,8, Daniel Birnbaum1 and Jocelyne Jacquemier*1,5
Address: 1Centre de Recherche en Cancérologie de Marseille, Département d'Oncologie Moléculaire, UMR599 Inserm; Institut Paoli-Calmettes; 
IFR137, Marseille, France, 2Département de Médecine, Institut Salah Azaiz, Tunis, Tunisie, 3Unité d'Epidémiologie Génétique et Moléculaire, 
Faculté de Médecine, Tunis, Tunisie, 4Département de Pathologie, Institut Salah Azaiz, Tunis, Tunisie, 5Département de BioPathologie, Institut 
Paoli-Calmettes, Marseille, France, 6UFR de Médecine, Université de la Méditerranée, Marseille, France, 7Département de Biostatistiques, Institut 
Paoli-Calmettes, Marseille, France and 8Département d'Oncologie Médicale, Institut Paoli-Calmettes, Marseille, France
Email: Azza Ben Hamida - azza.benhamida@gmail.com; Intidhar S Labidi - intidhar.labidi@voila.fr; Karima Mrad - karima.mrad@rns.tn; 
Emmanuelle Charafe-Jauffret - jauffrete@marseille.fnclcc.fr; Saïda Ben Arab - benarab_saida@yahoo.fr; 
Benjamin Esterni - esrternib@marseille.fnclcc.fr; Luc Xerri - xerril@marseille.fnclcc.fr; Patrice Viens - viensp@marseille.fnclcc.fr; 
François Bertucci - bertuccif@marseille.fnclcc.fr; Daniel Birnbaum - birnbaum@marseille.inserm.fr; 
Jocelyne Jacquemier* - jacquemierj@marseille.fnclcc.fr
* Corresponding author    
Abstract
Background: Inflammatory breast cancer (IBC) is a distinct and aggressive form of locally-advanced
breast cancer with high metastatic potential. In Tunisia, IBC is associated with a high death rate. Among
the major molecular subtypes, basal breast carcinomas are poorly differentiated, have metastatic potential
and poor prognosis, but respond relatively well to chemotherapy. The aim of this study was to determine
the distribution of molecular subtypes in IBC and identify factors that may explain the poor prognosis of
IBC.
Methods: To determine breast cancer subtypes we studied by immunohistochemistry the expression of
12 proteins in a series of 91 Tunisian IBC and 541 non-IBC deposited in tissue microarrays.
Results: We considered infiltrating ductal cases only. We found 33.8% of basal cases in IBC vs 15.9% in
non-IBC (p < 0.001), 33.3% of ERBB2-overexpressing cases in IBC vs 14.5% in non-IBC (p < 0.001), and
29.3% of luminal cases in IBC vs 59.9% in non-IBC (p < 0.001). The most differentially-expressed protein
between IBCs and non-IBCs was P-cadherin. P-cadherin expression was found in 75.9% of all IBC vs 48.2%
of all non-IBC (p < 0.001), 95% of IBC vs 69% of non-IBC (p = 0.02) in basal cases, and 82% of IBC vs 43%
of non-IBC (p < 0.001) in luminal cases. Logistic regression determined that the most discriminating
markers between IBCs and non-IBCs were P-cadherin (OR = 4.9, p = 0.0019) MIB1 (OR = 3.6, p = 0.001),
CK14 (OR = 2.7, p = 0.02), and ERBB2 (OR = 2.3, p = 0.06).
Conclusion: Tunisian IBCs are characterized by frequent basal and ERBB2 phenotypes. Surprisingly,
luminal IBC also express the basal marker P-cadherin. This profile suggests a specificity that needs further
investigation.
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Background
Inflammatory breast cancer (IBC) represents less than
10% of all breast cancers but is the most lethal form of the
disease [1]. Evolution of this distinct and aggressive form
of locally-advanced breast cancer depends on the type of
neo-adjuvant chemotherapy but is overall poor [2]. IBC,
classified T4d (stage IIIB) according to the TNM classifica-
tion of the American Joint Committee of Cancer [5], is
generally a rapidly growing tumor associated with cutane-
ous erythema and edema [2-4]. The inflammatory aspect
is associated with highly angiogenic and angio-invasive
properties and with the presence of dermal lymphatic
emboli [5]. The high metastatic potential of IBCs suggests
a high propensity of the tumor cells to migrate.
IBCs in Tunisia are characterized by a higher frequency
and a higher aggressiveness than in European countries
[6-8]. However, we did not observe any difference
between Tunisian and French IBCs in the expression of
five representative proteins (E-cadherin, Estrogen receptor
(ER), MIB1, MUC1 and ERBB2) [9,10].
In non-IBCs the five molecular subtypes (luminal A and B,
basal, ERBB2-overexpressing and normal-like) are associ-
ated with different features, including response to chemo-
therapy and clinical outcome [11]. Basal and ERBB2
subtypes have the worst prognosis, followed by luminal B
subtype. The proportion of these subtypes has been deter-
mined by gene expression profiling in European IBC.
Around half the cases are of basal and ERBB2 subtypes.
The subtypes defined by gene expression analysis have
also been defined at the protein level using various mark-
ers. A panel of antibodies (directed against ER, ERBB2,
EGFR, basal cytokeratin CK5/6 and/or KIT) identifies
basal tumors with high specifity [12]. Other markers such
as P-cadherin, CK14, P53, CAV1, PR, MIB1 and moesin
also identify basal tumors [13-16]. Reciprocally, the
expression of ER and ERBB2 exclude basal tumors.
The high frequency of the two subtypes associated with
poor prognosis, basal and ERBB2, explains only in part
the fatal evolution of IBC. In IBCs, the luminal cases also
have a poor prognosis. Only a factor common to all sub-
types could explain IBC poor evolution.
In breast cancer, P-cadherin is associated with enhanced
cell invasion, tumor aggressiveness, motility [17] and with
a poor prognosis [18,19]. P-cadherin mRNA is essentially
expressed in basal carcinomas [20,21].
The aims of this study were to determine the importance
of breast carcinoma subtypes in IBC and to identify a fac-
tor that could explain the poor prognosis of IBC. We show
that this factor could be associated with P-cadherin
expression.
Methods
Definition and selection of cases
We collected a series of 91 Tunisian T4d tumors (TNM,
UICC) treated between 1994 and 1998 at the Salah Azaiz
Institute (ISA, Tunis, Tunisia). Paraffin-embedded speci-
mens were collected prior chemotherapy. The presence of
dermal lymphatic emboli was not mandatory. All patients
received neo-adjuvant chemotherapy with anthracyclin-
based (FEC 100 or FAC 50) regimen. Forty-three patients
were metastatic at diagnosis and did not have comple-
mentary mastectomy. External beam radiation was done
for all patients.
This series was compared with a consecutive series of 547
non-IBC cases deposited in tissue microarrays and previ-
ously used in a study of IBC cases that established IBC
immunohistochemical profile [22] and for other pur-
poses [23]. The 547 non-IBC cases were selected from
cases included in the database of the Paoli-Calmettes
Institute (IPC, Marseille, France) treated between 1990
and 1999. They were defined as T1, T2, T3 tumors (TNM,
UICC), collected prior to adjuvant chemotherapy and
embedded in paraffin.
Clinicopathological study
The clinical records were reviewed to determine the fol-
lowing patient characteristics: age, metastatic status, ther-
apeutic regimen and survival. Pathological slides were
reviewed by two pathologists (JJ, KM) according to the
European guidelines [24]. Criteria evaluated were histo-
logical type, Elston-and-Ellis grade and, whenever possi-
ble, peritumoral vascular invasion.
Tissue Microarray construction
Two tissue microarrays (TMA) were used, one for the IBCs
(ISA set) and the other one for the non-IBCs (IPC set).
TMAs were prepared as described, with slight modifica-
tions [22-25]. Briefly, for each tumor, three representative
tumor areas were carefully selected from a hematoxylin-
eosin-safran stained section of a donor block. Core cylin-
ders with a diameter of 0.6 mm each were punched from
each of these areas and deposited into a recipient paraffin
block using a specific arraying device (Alphelys, Plaisir,
France). In addition to tumor tissues, the recipient blocks
also received normal breast tissues and cell lines. Five-μm
sections of the resulting microarray blocks were made and
used for IHC analysis after transfer to glass slides.
Markers and immunohistochemistry
Immunohistochemistry (IHC) was performed on 5-μm
sections. The characteristics of the antibodies used and
pre-treatment conditions are listed in Table 1. A good con-BMC Cancer 2008, 8:28 http://www.biomedcentral.com/1471-2407/8/28
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cordance of IHC results has been reported between stand-
ard full tissue sections and TMA [21]. TMA data were
evaluated by the mean score of two cores biopsies mini-
mum for each case. The slides were dewaxed, pre-treated
according to the supplier's recommendations (Table 1).
This was followed by the use of a streptavidin/biotin kit
(Dako, Trappes, France). Diaminobenzidine, (DAB) or 3-
amino-9-ethylcarbazole (AEC) was used as chromogen.
Sections were counterstained with hematoxylin and cov-
erslipped. Slides were evaluated under a light microscope
by two independent observers on the Spot Browser device
(Alphelys). Immunoreactivities were classified by estimat-
ing the percentage (P) of tumor cells showing characteris-
tic staining (from 0%, undetectable level, to 100%,
homogeneous staining) and by estimating the intensity
(I) of staining 1, weak staining; 2, moderate staining; 3,
strong staining). Results were scored by multiplying the
percentage of positive cells by the intensity, i.e. by the so-
called quick-score (Q). Internal positive controls such as
epidermis or benign breast lobules were used. Hormone
receptors (ER, PR) were positive when at least 1% of
tumor cell nuclei were stained. For ERBB2, the Dako scale
was used; staining was considered as positive when lim-
ited to a membrane staining of more than 10% of tumor
cells and scored as 1+, 2+ or 3+ according to intensity and
partial/complete staining. Protein overexpression was
considered for 2+ and 3+. Cytokeratin 5/6, cytokeratin 14
and EGFR were scored positive if any (weak or strong)
membranous invasive carcinoma cell staining was
observed. Caveolin 1 (CAV1) and Caveolin 2 (CAV2) sta-
tus of tumor cells was evaluated by light microscopy as
either positive (any tumor cell with IHC staining) or neg-
ative. For CAV1 negative cases, endothelial cells and inter-
stitial fibroblasts were used as internal positive controls.
Statistical analysis
Data were summarized by frequencies and percentages for
categorical variables. Furthermore, for continuous varia-
bles the means, the median and range were computed. To
investigate the association between categorical variables,
univariate statistical analysis were done, using Pearson's
Chi-2 test or Fisher's exact test for small sample size and
using non-parametric Mann and Whitney test for contin-
uous variables [26]. Multivariate analysis was done using
logistic regression model with backward stepwise selec-
tion procedure to evaluate the effect of interactions
between the different variables. All statistical tests were
two-sided at the 5% level of significance. All the statistical
analyses were done using R.2.4.0 statistical software[27].
Results
Characteristics of patients and tumors
A total of 91 IBC and 547 non-IBC informative cases from
women patients were analyzed. Their characteristics are
listed in Table 2. Age was different (p < 0.001) for the two
series: for IBCs, age ranged from 22 to 76 years (mean
Table 1: Main characteristics of the antibodies used in immunohistochemistry.
Protein (Clone) Antibody Origin Clone Pre-treatment Dilution Location of staining Normal
Caveolin 1 mmb Santa Cruz N20 Micro waves (10 min), 
tps citrate pH = 6
1/1000 cytoplasm m.e.c+
Caveolin 2 mmb Transduction 
Laboratories
65 Target retrival solution 
(98°C, 40 min)
1/50 cytoplasm m.e.c+
Cytokeratin 5/6 mmb Dako D5/16 B4 Target retrival solution 
(98°C, 40 min)
1/10 cytoplasm m.e.c +
Cytokeratin 14 mmb Newcastle UK LL002 Target retrival solution 
(98°C, 40 min)
1/300 Cell membrane m.e.c+
EGFR mmb Zymed 3IG7 Target retrival solution 
(98°C, 40 min)
1/10 membrane m.e.c +
ERBB2 mmb Dako 
Herceptest Ltd
AO485 Target retrival solution 
(98°C, 40 min)
1/500 membrane -
Estrogen receptor 
(ER)
mmb Novocastra 
laboratories Ltd
6F11.2 Target retrival solution 
(98°C, 40 min)
1/60 nucleus m.e.c- and luminal+
P53 mmb Dako DO-1 Target retrival solution 
(98°C, 40 min)
1/4 nucleus -
P-cadherin mmb Transduction 
laboratories
56 Target retrival solution 
(98°C, 40 min)
1/75 Cell membrane m.e.c +
Progesterone receptor 
(PR)
mmb Dako PFR 636 Target retrival solution 
(98°C, 40 min)
1/80 Nucleus m.e.c- and luminal+
Ki67 mmb Dako KI-67 Target retrival solution 
(98°C, 40 min)
1/100 Nuclear -
MUC1 mmb Transgen H23 none 1/1000 Apical/Cytoplamic +
mmb: mouse monoclonal antibody
m.e.c: myoepithelials cellsBMC Cancer 2008, 8:28 http://www.biomedcentral.com/1471-2407/8/28
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43.47 years) whereas for non-IBCs, age ranged from 25 to
94 years (mean 59.43 years).
Among the 91 IBCs, 86 were invasive ductal carcinomas
(IDC) and 5 were invasive micropapillary carcinomas.
The distribution of histological types in non-IBCs was rep-
resentative of unbiased populations. IBCs were more fre-
quently of grade II and III (65.93%, 30.77%) than non-
IBCs (p < 0.001) (Table 2).
Protein expression profiles of IBC and non-IBC and 
immunohistochemical subtypes
IHC was done on IBCs and non-IBCs using three TMA
slides for each marker. We compared the expression of the
markers only for the infiltrating ductal cases, i.e. 86 IBC
cases and 386 non-IBC cases. We observed differences
between the two series for: ER negativity (53.85% IBCs,
26.26 % non-IBCs; p < 0.001), PR negativity (52.86%
IBCs, 35.39% non-IBCs; p < 0.01), ERBB2 positivity
(33.33% IBCs, 14.49% non-IBCs; p < 0.001), CK14 posi-
tivity (19.15% IBCs, 5.45% non-IBCs; p < 0.01), P-cad-
herin positivity (75.93% IBCs, 48.16% non-IBCs; p <
0.001) (Figure 1) and proliferative rate expressed by a
Ki67 index (MIB1) higher than 20% (41.1% IBCs,
12.98% non-IBCs; p < 0.001) (Table 3).
We classified tumors in terms of subtypes based on ER/PR
and ERBB2 IHC expression [12,28]. The analysis was
restricted to the infiltrating ductal cases (86 IBC and 386
non-IBC), and allowed a classification in three groups
(Table 4). ER-positive and PR-positive tumors were classi-
fied as luminal. ERBB2-positive tumors were classified as
ERBB2-overexpressing. ER-negative and ERBB2-negative
(double negative) were considered as basal (ER-/ERBB2-).
Using this protein-based definition of subtypes, 33.8% of
IBCs vs 15.93 % of non-IBCs (p < 0.001) were basal,
33.33 % of IBCs vs 14.49% of non-IBCs (p < 0.001) were
ERBB2-overexpressing, and 29.33% of IBCs vs 58.93% of
non-IBCs (p < 0.001) were luminal.
Expression of P-cadherin in IBC and non-IBC
Univariate analyses
Among various markers tested, the expression of P-cad-
herin was worth further investigation. The expression of
P-cadherin varied according to the subtype and the IBC
status in infiltrating ductal cases. The expression of P-cad-
herin in the basal subtype was 95% for IBCs vs 69% for
non-IBCs (p = 0.02). There was no difference between
IBCs and non-IBCs in the ERBB2-overexpressing subtype.
In luminal tumors, P-cadherin was expressed in 82 % of
IBCs vs 43% of non-IBCs (p < 0.01) (Table 5). Finally, we
found a strong correlation between P-cadherin and Ki67/
MIB1 (p = 0.0004).
Multivariate analyses
We used a logistic regression stepwise selection with clin-
ical and biological factors (Table 6). The most discrimi-
nant factors for IBC status were grade (Odd ratio, OR =
6.28, p = 0.081), and P-cadherin (OR = 4.21, p = 0.013),
MIB1 (OR = 2.82, p = 0.018), and ER (OR = 1.00, p =
Table 3: Immunohistochemical comparison of the different 
markers used in the two series
IBC Non-IBC p value
n (%) n (%)
ER Negative 42 (53.85%) 99 (26.26%) <0.001
Positive 36 (46.15%) 278 (73.74%)
PR Negative 37 (52.86%) 132 (35.39%) <0.01
Positive 33 (47.14%) 241 (64.61%)
ERBB2 0–1 48 (66.67%) 301 (85.51%) <0.001
2–3 24 (33.33%) 51 (14.49%)
EGFR Negative 57 (77.03%) 240 (75.24%) >0.05
Positive 17 (22.97%) 79 (24.76%)
CK5/6 Negative 47 (61.04%) 191 (67.25%) >0.05
Positive 30 (38.96%) 93 (32.75%)
CK14 Negative 38 (80.85%) 295 (94.55%) <0.01
Positive 9 (19.15%) 17 (5.45%)
P-cadherin Negative 13 (24.07%) 169 (51.84%) <0.001
Positive 41 (75.93%) 157 (48.16%)
P53 Negative 43 (58.11%) 253 (69.7%) >0.05
Positive 31 (41.89%) 110 (30.3%)
MUC1 Negative 5 (6.67%) 42 (12.84%) >0.05
Positive 70 (93.33%) 285 (87.16%)
CAV1 Negative 22 (31.43%) 105 (31.16%) >0.05
Positive 48 (68.57%) 232 (68.84%)
CAV2 Negative 45 (90%) 212 (89.83%) >0.05
Positive 5 (10%) 35 (10.17%)
MIB1 ≤20 43 (58.9%) 295 (87.02%) <0.001
>20 30 (41.1%) 44 (12.98%)
Table 2: Clinical and histological characteristics of IBC and non-
IBC cases.
Variables IBC Non-IBC p
Age
Min 22 25
Max 76 94 <0.001
Mean 43.47 59.43
Standard deviation 9.43 12.77
Grade
I 3(3.3%) 176(32.41%)
II 60(65.93%) 229(42.17%) <0.001
III 28(30.77%) 138(25.41%) *
Histological type
Invasive ductal carcinoma 86(94.5) 386(70.56)
Micropapillary carcinoma 5(5.5) 0
Lobular carcinoma 0 72(13.16)
Tubular carcinoma 0 37(6.76) <0.001
Mixt 0 24(4.38)
Medullary carcinoma 0 8(1.46)
Others 0 20(3.65)
* 4 cases non valuable for the histoprognostic grade.BMC Cancer 2008, 8:28 http://www.biomedcentral.com/1471-2407/8/28
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0.053) expression. In a logistic regression by backward
stepwise selection using biological factors only, the factors
discriminating IBC from non-IBC were P-cadherin (OR =
4.9, p = 0.0019), MIB1 (OR = 3.6, p = 0.001), CK14 (OR
= 2.7, p = 0.02), and ERBB2 (OR = 2.3, p = 0.06).
Discussion
The identification of a specific IBC profile could improve
the diagnosis, treatment and evolution of this aggressive
form of locally-advanced breast cancer with high meta-
static potential. In Tunisia, IBCs are frequent and have a
worse prognosis than in European countries. However, in
a previous study, we did not observe any difference in pro-
tein expression between IBCs from France and Tunisia
Table 5: Comparison of P-cadherin expression in different breast 
cancer subtypes
IBC Non-IBC p-value
n(%) n(%)
Basal cases (ER-,ERBB2-) 18/19(95%) 35/51(69%) 0.05
ERBB2-overexpressing cases 9/13(69%) 32/47(68%) NS
Luminal cases (ER+, PR+) 14/17(82%) 84/197(43%) <0.01
Immunohistochemistry on tissue microarray sections of breast cancers of the luminal subtype Figure 1
Immunohistochemistry on tissue microarray sections of breast cancers of the luminal subtype. A: Expression of 
estrogen receptor in 100% of tumor cells in a grade III inflammatory case. B: Strong expression of P-cadherin in 100% of tumor 
cells in the same case. C: Higher magnification showing the cell membrane localization. D: Expression of estrogen receptor in 
100 % of tumor cells in a more differentiated (grade II) inflammatory case. E: Moderate expression of P- cadherin in 100% of 
tumor cells in the same case. F: Higher magnification showing the cell membrane localization. G: Luminal grade II non inflamma-
tory case with 100% estrogen receptor-positive cells. H: Absence of expression of P-cadherin in the same non inflammatory 
case; note the positive internal control on myoepithelial cells of the normal duct. I: Higher magnification showing the cell mem-
brane localization of the myoepithelial cells by contrast to the negativity of the luminal normal cells.
A
B
D
E
C F
G
H
I
Table 4: Immunohistochemical classification in molecular 
subtypes of the two series
IBC Non-IBC
n (%) n (%) p value
Basal cases (ER-, ERBB2-) 24 (33.8%) 58 (15.93%) <0.001
ERBB2-overexpressing cases 24 (33.33%) 51 (14.49%) <0.001
Luminal cases (ER+, PR+) 22 (29.33%) 221 (58.93%) <0.001BMC Cancer 2008, 8:28 http://www.biomedcentral.com/1471-2407/8/28
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[10]. Five major molecular subtypes have been defined by
gene expression profiling [11,20,29]. Basal and ERBB2
subtypes represent each about 20% of cases. These sub-
types could also be recognized at the protein level, with a
very good correlation with RNA analyses. IHC-defined
subtypes also show differences in prognosis in non-IBCs:
basal and ERBB2-overexpressing subtypes are associated
with poor prognosis. To better understand the specificity
and the poor prognostic of IBCs in general and Tunisian
IBCs in particular, we studied by IHC on TMA the expres-
sion of proteins commonly used as markers for molecular
subtypes.
We studied several markers but eventually used a simple
operational definition based on ER and ERBB2 expres-
sion. The basal subtype was defined as negative for both
ER and ERBB2. In non-IBCs basal and ERBB2 subtypes
represent around 40% of cases. We compared only infil-
trating ductal cases. We found differences in the propor-
tion of subtypes in Tunisian IBCs. Basal and ERBB2
subtypes made up each about one-third of the cases. Over-
all, these data and those of the literature show an over-
representation of basal and ERBB2 cases in IBCs as com-
pared with non-IBCs [30,31].
However, the high proportion of basal and ERBB2 sub-
types is not sufficient per se to explain IBC prognosis. Only
a factor common to all subtypes could explain IBC poor
evolution. Surprisingly, we found that luminal IBCs
express basal markers such as P-cadherin. Indeed, P-cad-
herin expression was not only higher in basal IBCs than in
basal non-IBCs (95%/69%) but also higher in the IBC
luminal cases (82%/42%). The logistic regression analysis
showed that P-cadherin was the most representative
marker of IBC.
P-cadherin is one of the most specific markers of myoepi-
thelial cells and is associated with basal subtype. The fre-
quency of P-cadherin IHC expression varies from 20% in
initial works [32] to 40% in more recent series[33]. This
percentage exceeds that of basal tumors suggesting that P-
cadherin could also be expressed in non-basal cases. P-
cadherin expression in breast cancer correlates with high
grade, lack of ER/PR expression, increased tumor aggres-
siveness, high proliferation rate, and poor survival. P-cad-
herin is associated with MIB1, EGFR, ERBB2, P53 and
CK5/6 expression [23]. This expression may be due to
hypomethylation of the gene promoter [18]. Deregulated
P-cadherin expression may alter epithelial cell behavior
thereby contributing to a more aggressive tumor cell phe-
notype and poor survival [34]. P-cadherin has pro-inva-
sive activity in the MCF-7/AZ luminal breast cancer cell
line, through interaction with signaling proteins bound to
its juxtamembrane domain. ICI182,780, which blocks ER,
induces increased expression of P-cadherin, which is asso-
ciated with in vitro invasion[35]. Overexpressed P-cad-
herin increases motility of pancreatic cancer cells by
interacting with p120ctn and subsequent activation of
RHO GTPases [36]. Activation of RHO GTPases has been
observed in IBC. Overexpression of RHOC is associated
with the loss of expression of WISP3 [37,38], which acts
as a tumor suppressor. RHOC is overexpressed in over
90% of IBCs vs 36% of non-IBCs. RHOC activity requires
NFκB stimulation [39]. P-cadherin transgenic mice do not
develop mammary tumors spontaneously. When mam-
mary tumors are induced in the P-cadherin transgenic
mice through breeding with the MMTV/neu transgenic
mouse, the tumors do not express P-cadherin. This indi-
cates that P-cadherin is not per se an oncogene [34].
Conclusion
Expression of P-cadherin in luminal IBC may indicate that
the tumor cells derive from a stem/basal cell that has
acquired ER expression and a luminal phenotype but
retained some basal features. This suggests that IBC
derives from a basal cell and progress along a specific
oncogenic pathway allowing partial differentiation. This
origin may be associated with specific IBC features and
aggressiveness even in luminal cases. Although it may
contribute, P-cadherin expression may be a sign of but not
the reason for this aggressiveness.
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